Drug metabolism and pharmacokinetics
…, R Whomsley, I Poggesi, W Cawello… - Drug metabolism …, 2009 - Taylor & Francis
In this article, aspects of absorption, distribution, metabolism, and excretion have been
described bearing in mind the pathogenesis of allergic diseases and their possible therapeutic …
described bearing in mind the pathogenesis of allergic diseases and their possible therapeutic …
Clinical pharmacokinetic and pharmacodynamic profile of lacosamide
W Cawello - Clinical pharmacokinetics, 2015 - Springer
Lacosamide—a third-generation antiepileptic drug available in multiple formulations—was
first approved in 2008 as adjunctive therapy for partial-onset seizures (POS) in adults. In 2014…
first approved in 2008 as adjunctive therapy for partial-onset seizures (POS) in adults. In 2014…
[HTML][HTML] An update on pharmacological, pharmacokinetic properties and drug–drug interactions of rotigotine transdermal system in Parkinson's disease and restless …
JP Elshoff, W Cawello, JO Andreas, FX Mathy, M Braun - Drugs, 2015 - Springer
This narrative review reports on the pharmacological and pharmacokinetic properties of
rotigotine, a non-ergolinic D 3 /D 2 /D 1 dopamine receptor agonist approved for the treatment of …
rotigotine, a non-ergolinic D 3 /D 2 /D 1 dopamine receptor agonist approved for the treatment of …
Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies
…, M Braun, JO Andreas, M Middle, W Cawello - Clinical …, 2012 - Elsevier
BACKGROUND: The dopamine agonist rotigotine is formulated in a transdermal delivery
system (patch) for once-daily application. It has been reported as efficacious in the treatment of …
system (patch) for once-daily application. It has been reported as efficacious in the treatment of …
No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers
W Cawello, B Nickel… - The Journal of Clinical …, 2010 - Wiley Online Library
Lacosamide is a new antiepileptic drug for adjunctive treatment of adult partial‐onset seizures.
Two open‐label, multiple‐dose clinical trials were conducted to evaluate the potential for …
Two open‐label, multiple‐dose clinical trials were conducted to evaluate the potential for …
Advances in epilepsy treatment: lacosamide pharmacokinetic profile
W Cawello, A Stockis, JO Andreas… - Annals of the new York …, 2014 - Wiley Online Library
Lacosamide (LCM) is a functionalized amino acid specifically developed for use as an
antiepileptic drug (AED) and is currently indicated as adjunctive treatment for partial‐onset …
antiepileptic drug (AED) and is currently indicated as adjunctive treatment for partial‐onset …
Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy …
W Cawello, B Rosenkranz, B Schmid, W Wierich - Epilepsia, 2013 - Wiley Online Library
Purpose To determine whether the antiepileptic drug lacosamide affects the pharmacokinetics
or pharmacodynamics of a combined oral contraceptive ( OC ; ethinylestradiol 0.03 mg …
or pharmacodynamics of a combined oral contraceptive ( OC ; ethinylestradiol 0.03 mg …
Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration
W Cawello, H Boekens, R Bonn - European journal of drug metabolism …, 2012 - Springer
The absorption, distribution, metabolism and elimination of the anti-epileptic drug
lacosamide were determined in 10 healthy male volunteers following intravenous or oral …
lacosamide were determined in 10 healthy male volunteers following intravenous or oral …
Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of …
W Cawello, H Bökens, B Nickel, JO Andreas… - …, 2013 - Wiley Online Library
Purpose: To test for bioequivalence of 200 mg lacosamide oral tablet and syrup formulations.
Additional objectives were to compare the pharmacokinetic profile of lacosamide in saliva …
Additional objectives were to compare the pharmacokinetic profile of lacosamide in saliva …
Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
W Cawello, M Braun, H Boekens - Drug metabolism and disposition, 2009 - ASPET
The dopamine agonist rotigotine was developed for the treatment of Parkinson's disease and
restless legs syndrome. Disposition, metabolism, elimination, and absolute bioavailability …
restless legs syndrome. Disposition, metabolism, elimination, and absolute bioavailability …